Yang Pu is an Associate Professor at the Institute of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College. She obtained tumor immunology training in University of Chicago, supervised by Dr. Yangxin Fu during her Ph.D study. She has been involved in reporting that adaptive immunity is required for anti-tumor efficacy by various radiation, chemotherapies, and hormone-related therapies. Such conventional therapy can induce innate sensing that bridges to adaptive immunity that control tumor or limit local or distal relapse. Those studies help to better integrate conventional therapy with various immunotherapies. Her team is now interested in exploring novel mechanisms for cancer therapies bridging innate and adaptive immune responses and exploring the regulation of novel post-translation modification in tumor microenvironment.
l GOLM1 restricts colitis and colontumorigenesis by ensuring Notch signaling equilibrium in intestinal homeostasis, Yang Pu* (first and corresponding), Ya Song, Mengdi Zhang, Caifeng Long, Jie Li, Yanan Wang, Yinzhe Xu, Fei Pan, Na Zhao, Xinyu Zhang, Yanan Xu, Jianxin Cui, Hongying Wang, Yan Li, Yong Zhao, Di Jin*, Hongbing Zhang*, Signal Transduction and Targeted Therapy, 2021 Apr 14;6(1):148.
l Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse, Yang Pu; Meng Xu; Yong Liang; Kaiting Yang; Yajun Guo; Xuanming Yang*; Yangxin Fu*; Science Translational Medicine, 2016, 8(333): ra47.
l Mapping and targeting proteome of mitotic pericentriolar material for killing tumors bearing centrosome amplification, Bingteng Xie, Yang Pu (co-first author), Fan Yang, Wei Chen, Wei Yue, Jihong Ma, Zhang, Yuening Jiang, Jiegen Wu, Yihan Lin, Xin Liang, Chu Wang, Peng Zou, and Mo Li, Cancer Research, 2022 Jul 18;82(14):2576-2592
l Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2, Shiyu Sun, Yueqi Cai , Tian-Zhang Song, Yang Pu (co-first author), Lin Cheng , Hairong Xu , Jing Sun , Chaoyang Meng, Yifan Lin , Haibin Huang , Fang Zhao , Silin Zhang , Yu Gao , Jian-Bao Han , Xiao-Li Feng , Dan-Dan Yu , Yalan Zhu , Pu Gao, Haidong Tang, Jincun Zhao , Zheng Zhang, Jiaming Yang, Zhenxiang Hu, Yang-Xin Fu, Yong-Tang Zheng , Hua Peng*,Cell Research, 2021 Jul 15;1-13.
l Dissecting esophageal squamous-cell carcinoma ecosystem by single-cell transcriptomic analysis. Z hang X, Peng L, Luo Y, Zhang S, Pu Y (co-first author), Chen Y, Guo W, Yao J, Shao M, Fan W, Cui Q, Xi Y, Sun Y, Niu X, Zhao X, Chen L, Wang Y, Liu Y, Yang X, Wang C, Zhong C, Tan W, Wang J, Wu C, Lin D. Nature Communications, 2021 Sep 6;12(1):5291. doi: 10.1038/s41467-021-25539-x.
l Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling. Xu MM, Pu Y, Han D, Shi Y, Cao X, Liang H, Chen X, Li XD, Deng L, Chen ZJ, Weichselbaum RR, Fu YX. Immunity. 2017 Aug 15;47(2):363-373.e5.
l CD47 blockade triggers T cell–mediated destruction of immunogenic tumors, Xiaojuan Liu; Yang Pu; Kyle Cron; Liufu Deng; Justin Kline; William A Frazier; Hairong Xu; Hua Peng; Yang-Xin Fu*; Meng Michelle Xu; Nature Medicine, 2, 1209-1215. 015 21(10)